retatrutide phase 2 trial results weight loss obesity triple agonist This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/jNL1GNnHPT #Endocrinology Eli Lilly said Thursday its

Thyroid C-Cell Tumors Animal studies have linked semaglutide drugs like Wegovy to thyroid C-cell tumors, and while human data is still limited, warnings are included on the drugs label

Members under 21 may still qualify via EPSDT, and non-weight-loss indications (like Zepbound for sleep apnea) may still get prior authorization

At Adonis Saremi, MD , our Microdosing GLP-1 Program in Irvine, CA offers a physician-designed alternative: precisely calibrated sub-standard doses that preserve the metabolic and appetite-regulation benefits of GLP-1 medications while minimizing the side-effect burden that causes many patients to discontinue

Tirzepatide pros Effective for weight loss : Tirzepatide has shown significant weight loss results, with some patients losing over 20% of their body weight, especially in people with obesity